229 related articles for article (PubMed ID: 36309362)
1. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
[TBL] [Abstract][Full Text] [Related]
2. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
[No Abstract] [Full Text] [Related]
3. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
Kim HS; DO SI; Kim DH; Apple S
Anticancer Res; 2020 Mar; 40(3):1487-1494. PubMed ID: 32132048
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(9):e0257860. PubMed ID: 34559865
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
BMC Cancer; 2021 Mar; 21(1):239. PubMed ID: 33676425
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
9. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
11. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
Tomioka N; Hatanaka KC; Okuyama D; Watanabe KI; Yamamoto M; Maeda H; Tachikawa H; Kuwahara S; Shimizu A; Suzuki H; Hatanaka Y; Takahashi M
Breast Cancer; 2023 May; 30(3):497-505. PubMed ID: 36892732
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
[TBL] [Abstract][Full Text] [Related]
15. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Li Y; Vennapusa B; Chang CW; Tran D; Nakamura R; Sumiyoshi T; Hegde P; Molinero L
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):258-264. PubMed ID: 33030848
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
19. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
[TBL] [Abstract][Full Text] [Related]
20. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
